# IASO207 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies

> **NCT07574346** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 18 (estimated)

## Conditions studied

- Malignancies

## Interventions

- **DRUG:** IASO207 Injection

## Key facts

- **NCT ID:** NCT07574346
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2029-04-30
- **Final completion:** 2042-04-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07574346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07574346, "IASO207 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT07574346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*